December 2025 in “Journal of Human Immunity” JAK inhibitors may help improve symptoms in adults with APECED.
7 citations
,
March 2023 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” July 2024 in “Journal of Investigative Dermatology” Brepocitinib improves cicatricial alopecia and reduces key immune markers.
60 citations
,
January 2004 in “The journal of investigative dermatology/Journal of investigative dermatology” Applying a specific inhibitor lightens skin and hair color.
February 2025 in “Archives of Dermatological Research” Polynucleotides effectively promote hair regrowth in androgenetic alopecia without serious side effects.
173 citations
,
July 2012 in “British Journal of Dermatology” Dabrafenib can cause skin growths and sometimes low-grade skin cancer.
LGF injections may improve early Peyronie's disease by reducing penile curvature and plaque size.
103 citations
,
April 2005 in “Experimental dermatology” Prostaglandin F2alpha and related compounds can increase hair growth and darken hair in mice.
April 2023 in “Journal of The American Academy of Dermatology” Some drugs linked to growth hormones may increase the chance of hair loss in women.
January 2016 in “The Australian Pharmacist” Tofacitinib might be used to treat hair loss.
August 2003 in “Journal of Investigative Dermatology” Phosphatidic acid may promote hair growth like minoxidil.
September 2019 in “Journal of Investigative Dermatology” PCE-DP brightens skin and promotes hair growth by enhancing cell growth and reducing melanin uptake.
1 citations
,
July 2024 in “Journal of Investigative Dermatology” VYN201 shows promise as a safe and effective treatment for non-segmental vitiligo.
September 2017 in “The journal of investigative dermatology/Journal of investigative dermatology” N-acetyl-GED may help prevent and partially reverse a process that leads to scarring hair loss.
9 citations
,
January 2023 in “Dermatology and therapy” A 14-year-old girl with severe hair loss regrew her hair using upadacitinib.
November 2023 in “Research Portal Denmark” Baricitinib shows promise for severe alopecia areata but isn't a cure and has side effects.
21 citations
,
June 2017 in “Case Reports in Dermatology” Reducing gefitinib dosage improved hair loss, but scarring remained.
TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.
TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.
November 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” ARQ-234, a protein designed to treat atopic dermatitis, shows increased effectiveness in early testing.
8 citations
,
March 2023 in “PubMed” JAK inhibitors show promise in treating difficult skin diseases.
1 citations
,
November 2023 in “SKIN The Journal of Cutaneous Medicine” September 2019 in “The journal of investigative dermatology/Journal of investigative dermatology” PPARγ signaling modulation can protect hair follicle stem cells from chemotherapy-induced damage.
August 2024 in “Biomolecules & Therapeutics” A new compound, HTPI, promotes hair growth by protecting cells from damage and regulating energy use.
Ritlecitinib significantly regrows scalp hair in people with alopecia areata.
13 citations
,
January 2010 in “Immunopharmacology and immunotoxicology” Diphencyprone increases Bcl-2 protein in patients with hair regrowth from alopecia areata.
68 citations
,
September 2003 in “British Journal of Dermatology” Shrinking skin cancer increases the chance of cancer in nearby lymph nodes.
June 2023 in “Clinical Cosmetic and Investigational Dermatology” Pentoxifylline effectively improves pretibial pruritic papular dermatitis.
November 2022 in “Munich Personal RePEc Archive (Ludwig Maximilian University of Munich)” Phosphatidylinositol 4-kinases are crucial for root growth, defense, and immunity in Arabidopsis thaliana.
26 citations
,
June 2005 in “Journal of The American Academy of Dermatology” Some patients receiving pegylated interferon alfa injections developed skin necrosis, requiring treatment adjustments or discontinuation.